InMed stock rallied yesterday on a merger announcement with Mentari Therapeutics. Here’s why the transaction is concerning ...

Canadian pharmaceutical company InMed Pharmaceuticals (INM) added ~170% in the premarket on Tuesday after announcing an all-stock merger agreement with migraine drug developer Mentari Therapeutics to ...

InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with ...

The merger shifts InMed toward migraine prevention therapies while a large private financing is expected to fund operations ...

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...

View InMed Pharmaceuticals Inc. INM stock quote prices, financial information, real-time forecasts, and company news from CNN.

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders ...

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed ...

Jumping into the health and wellness sector once seemed like an easy win for some pharma companies, but the tough times are increasingly extending beyond biotech. That certainly seems to be the case ...

InMed Pharmaceuticals is a Vancouver-based pre-clinical trial biotech company that has not only developed a proprietary cannabinoid manufacturing system but in the process created a highly sought ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.